Delivery of Dihydroergotamine Mesylate to the Upper Nasal Space for the Acute Treatment of Migraine: Technology in Action
Journal of Aerosol Medicine and Pulmonary Drug Delivery · 01.12.2022 · 35 (6) · 321-332
DOI: 10.1089/jamp.2022.0005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Aerosol Medicine and Pulmonary Drug Delivery, online erschienen am 13.12.2022. Verfasst von Wade Cooper und 6 weiteren Autor:innen. Beteiligte Einrichtung: Headache and Neuropathic Pain Program, University of Michigan, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Dihydroergotamine, Migraine Disorders. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Oral tablets account for the majority of medications used to acutely treat migraine, but relief can be limited by their rates of dissolution and absorption. The nose is an attractive alternative route of drug delivery since it provides patient convenience of at-home use, gastrointestinal (GI) avoidance, and rapid absorption of drugs into systemic circulation because of its large surface area. However, the site of drug deposition within the nasal cavity should be considered since it can influence drug absorption. Traditional nasal devices have been shown to target drug delivery to the lower nasal space where epithelium is not best-suited for drug absorption and where there is an increased likelihood of drug clearance due to nasal drip, swallowing, or mucociliary clearance, potentially resulting in variable absorption and suboptimal efficacy. Alternatively, the upper nasal space (UNS) offers a permeable, richly vascularized epithelium with a decreased likelihood of drug loss or clearance due to the anatomy of this area. Traditional nasal pumps deposit
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Headache and Neuropathic Pain Program, University of Michigan, Ann Arbor, Michigan, USA.
- Impel Pharmaceuticals, Seattle, Washington, USA.
ORCID-Profile: Stephen B Shrewsbury
Zitieren
APA
Cooper, W., Ray, S., Aurora, S. K., Shrewsbury, S. B., Fuller, C., Davies, G., & Hoekman, J. (2022). Delivery of Dihydroergotamine Mesylate to the Upper Nasal Space for the Acute Treatment of Migraine: Technology in Action. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 35(6), 321-332. https://doi.org/10.1089/jamp.2022.0005
Vancouver
Cooper W, Ray S, Aurora SK, Shrewsbury SB, Fuller C, Davies G, et al. Delivery of Dihydroergotamine Mesylate to the Upper Nasal Space for the Acute Treatment of Migraine: Technology in Action. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2022;35(6):321-332. doi:10.1089/jamp.2022.0005
BibTeX
@article{Cooper2022,
author = {Cooper, Wade and Ray, Sutapa and Aurora, Sheena K and Shrewsbury, Stephen B and Fuller, Christopher and Davies, Greg and Hoekman, John},
title = {Delivery of Dihydroergotamine Mesylate to the Upper Nasal Space for the Acute Treatment of Migraine: Technology in Action},
journal = {Journal of Aerosol Medicine and Pulmonary Drug Delivery},
year = {2022},
volume = {35},
number = {6},
pages = {321--332},
doi = {10.1089/jamp.2022.0005}
}
EUVIMED